Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New bone putty could improve spinal surgery outcomes

NCT ID NCT07044206

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two bone substitutes used during spinal fusion surgery for disc degeneration. One is a new material designed to help bones fuse more effectively. Researchers will track 100 adults for 12 months to see if the new substitute improves pain, disability, and fusion rates compared to the standard option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MagnetOs bone substitute
What this could lead to
If successful, this could lead to better bone fusion after spinal surgery, reducing pain and the need for repeat operations.
What could go wrong
This is a small, early-stage study with only 100 participants. The new bone substitute may not work better than existing options, and surgery always carries risks like infection or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 18 and 80 years inclusive * Oswestry Disability Index (ODI) \>25 * Chronic low back pain and/or radicular pain lasting for more than 6 months * Failure of medical and rehabilitative treatment * Patient presenting with one of the following: grade 1 degenerative spondylolisthesis without isthmic lysis, or disc degeneration, or mixed pathology (degeneration and lumbar stenosis) * Patient eligible for anterior approach spinal fusion surgery with interbody cage Exclusion Criteria: * History of spinal surgery at the lumbar level, excluding isolated discectomies for disc herniation * Confirmed osteoporosis * Surgical fusion at an adjacent level * Contraindication to Magnetos Putty or GlassBone Putty: 1. Use of medications interfering with calcium metabolism 2. Severe systemic or metabolic bone disorders affecting bone healing or lesions 3. Untreated acute or chronic infection requiring appropriate therapy 4. Patients with severe trauma and open external wounds near the defect site, at risk of infection 5. Known allergy to bioactive glass or its components (Ca2+, PO43-, Na+, and Si(OH)4), polyethylene glycol, and/or glycerol 6. Patients who have undergone or will undergo chemotherapy or radiotherapy at or near the implantation site 7. Severe renal or hepatic infections 8. Unrepaired dural tear in craniospinal surgery * Patients requiring placement of more than one implant * Subject unable to read and/or write fluent French, or illiterate * Subject already participating in another interventional clinical trial that could interfere with this study * Uncontrolled psychiatric illness * Lack of written informed consent after a reflection period * Individuals with a dependency or employment relationship with the sponsor or investigator * Subject enrolled in another study with an ongoing exclusion period (Article L1121-12) * Subject not affiliated with or not a beneficiary of the French social security system (L1121-8-1) * Protected populations under French Public Health Code: 1. Pregnant or breastfeeding women (L. 1121-5) 2. Individuals deprived of liberty (art. L. 1121-6) (by judicial, administrative decision or involuntary hospitalization) 3. Protected adults (under guardianship, curatorship, or legal protection) (L. 1121-8) * Women planning to become pregnant within the year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Degenerative disc disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Montpellier

    RECRUITING

    Montpellier, France, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.